Antiarrhythmic therapy in atrial fibrillation: indications, guidelines, and safety.
Armin Barekatain, Mehdi Razavi
Author Information
- Armin Barekatain: Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
No abstract text available.
- Int J Cardiol. 2003 Feb;87(2-3):121-8
[PMID: 12559528]
- J Am Coll Cardiol. 2011 Mar 15;57(11):e101-98
[PMID: 21392637]
- Heart. 2000 Sep;84(3):339-46
[PMID: 10956304]
- N Engl J Med. 2008 Jun 19;358(25):2678-87
[PMID: 18565860]
- Lancet. 2012 Feb 18;379(9816):648-61
[PMID: 22166900]
- Pacing Clin Electrophysiol. 1992 Nov;15(11 Pt 2):2097-102
[PMID: 1279606]
- Pharmacol Ther B. 1975;1(1):115-38
[PMID: 772700]
- Tex Heart Inst J. 2005;32(2):209-11
[PMID: 16107117]
- Br J Clin Pharmacol. 1998 Oct;46(4):307-19
[PMID: 9803978]
- Circulation. 1982 May;65(5):886-94
[PMID: 6176355]
- N Engl J Med. 1989 Aug 10;321(6):406-12
[PMID: 2473403]
- J Am Coll Cardiol. 2001 Feb;37(2):542-7
[PMID: 11216976]
- J Am Coll Cardiol. 2009 Sep 15;54(12):1089-95
[PMID: 19744618]
- Circulation. 1991 Jun;83(6):1987-94
[PMID: 2040051]
- Eur Heart J. 1984 Feb;5(2):115-25
[PMID: 6144546]
- Cardiovasc Drugs Ther. 1992 Oct;6(5):519-28
[PMID: 1333276]
- Am J Cardiol. 1996 Jan 25;77(3):53A-59A
[PMID: 8607392]
Anti-Arrhythmia Agents
Atrial Fibrillation
Heart Conduction System
Humans
Patient Safety
Patient Selection
Practice Guidelines as Topic
Treatment Outcome
